GUILFORD, Conn. USA, February 24, 2022 — InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery and development, today announced that the Company will participate in the Truist Securities AI Symposium – Biotech & Tools.
Krishnan Nandabalan, Ph.D., the Company's President and CEO, will be participating in the panel: Integrated Platforms for AI-Based Drug Discovery at 11:20 am – 12:20 pm EST, moderated by Robyn Karnauskas, Senior Research Analyst and Kripa Devarakonda, Research Analyst, Truist Securities.
The panel will bring together leaders in AI-based drug discovery to discuss how integrated platforms are transforming the pharmaceutical research and development landscape, accelerating the path from target identification to clinical candidate.
InveniAI's AlphaMeld® platform has been validated through successful collaborations with leading industry players, including Kyowa Kirin, Shionogi, GSK, Centrexion, and Sosei Heptares. The company's track record includes candidates that have progressed to various stages of clinical development, including one program that reached successful Phase 3 trials and an NDA submission.